The KCTD12 Knockout NCI-H1975 Polyclonal Cells product provides a ready-to-use CRISPR/Cas9-edited polyclonal knockout cell population for functional studies of the KCTD12 gene. This loss-of-function model is generated by target-gene disruption in a heterogeneous pool of NCI-H1975 cells, enabling researchers to investigate KCTD12-dependent mechanisms without clonal selection biases. The polyclonal format preserves genetic diversity while abrogating KCTD12 expression, making it suitable for experiments that benefit from population-level analyses of gene function. As a research tool, it supports a broad range of assays in cell signaling, cancer biology, and drug discovery.
The parental NCI-H1975 cell line is a well-established human lung adenocarcinoma model derived from a non-small cell lung cancer (NSCLC) patient. These epithelial cells harbor activating EGFR mutations, specifically L858R and T790M, which drive constitutive kinase activity and confer resistance to first-generation tyrosine kinase inhibitors. NCI-H1975 is widely employed to study EGFR-driven oncogenic signaling, mechanisms of acquired drug resistance, and the evaluation of next-generation targeted therapies. The presence of endogenous EGFR mutations makes this background particularly relevant for dissecting cross-talk between EGFR downstream pathways and WNT/??-catenin signaling in the context of lung cancer.
KCTD12 functions as a substrate recognition adaptor for the Cullin3-RING E3 ubiquitin ligase complex, where it interacts with CUL3 and RBX1 to mediate ubiquitination and proteasomal degradation of target proteins. A key downstream target is ??-catenin (CTNNB1), the central transducer of canonical WNT signaling; KCTD12-promoted degradation of ??-catenin suppresses the WNT/??-catenin pathway. The gene is subject to upstream epigenetic silencing through promoter hypermethylation, leading to reduced expression in multiple cancers. In addition, KCTD12 binds to GABAB receptor subunits (GABBR1 and GABBR2) and modulates their trafficking and signaling, connecting it to GABAergic neurotransmission. The WNT pathway components that act upstream of ??-catenin include WNT ligands, Frizzled receptors, and the destruction complex composed of AXIN, APC, GSK3??, and ??-catenin itself, with KCTD12 serving as a negative regulator at the level of ??-catenin turnover.
In the NCI-H1975 lung adenocarcinoma context, loss of KCTD12 removes a brake on WNT/??-catenin signaling, potentially enhancing tumorigenic properties such as proliferation, invasion, and drug resistance. Given that KCTD12 is frequently silenced by promoter methylation in NSCLC and other cancers, this knockout model mimics a clinically relevant loss-of-function state. It enables the dissection of whether KCTD12 inactivation synergizes with EGFR mutations to alter downstream transcriptional programs, influence epithelial-to-mesenchymal transition, or modify sensitivity to EGFR inhibitors and chemotherapeutics. Furthermore, the interaction between KCTD12 and GABAB receptors suggests that this system could be used to explore potential non-canonical roles of neurotransmitter receptor modulation in cancer cell biology.
Researchers can apply this polyclonal knockout cell population in a variety of experimental workflows. Co-immunoprecipitation and ubiquitination assays can probe the interaction between CUL3/RBX1 and novel substrates or confirm altered ??-catenin ubiquitination. TOPFlash/FOPFlash luciferase reporter assays provide a direct readout of WNT/??-catenin transcriptional activity, while RT-qPCR and Western blotting quantify changes in pathway components such as ??-catenin, GSK3??, or GABBR1. Cell viability, apoptosis, and drug sensitivity assays (e.g., to gefitinib or osimertinib) are well-suited for assessing functional consequences in the EGFR-mutant background. Immunofluorescence can visualize ??-catenin subcellular localization, highlighting nuclear accumulation upon pathway activation. For additional information, please contact Ascent Research.
